Molecular Therapeutics of Cancer Research Conference -- 2012

Sponsored by the Cancer Molecular Therapeutics Research Association

Schedule and Program

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

NOTE: ALL SCIENTIFIC SESSIONS and POSTERS WILL BE HELD IN the Lewis Thomas Laboratories. Lodging will be in the Forbes Dormitories. Meals will be served in the Wilson Dining Hall and Forbes.

SUNDAY – JULY 15

3:00 pm	Arrival and check-in
6:00 – 7:30 pm	Buffet Dinner—Forbes Patio
7:30 – 7:45 pm	Welcome / Introductory Comments Peter Houghton, Nationwide Children's Hospital, Columbus, OH President CMTRA and Edward Sausville, University of Maryland, Baltimore, MD, Program Chair
7:45 – 10:00 pm	EVENING SESSION: "Emerging issues in breast cancer treatment"
	Discussion Leader: Pamela Munster, University of California, San Francisco
7:45 – 8:00 pm	Introduction & Overview
8:00 – 8:40 pm	Robert Clarke, Georgetown University, Washington DC "New Approaches to Studying Endocrine Resistance in Breast Cancer"
8:40 – 9:00 pm	Discussion
9:00 – 9:40 pm	Larry Norton, Memorial Sloan-Kettering Cancer Center, New York, NY "Self-Seeding as a Mechanism for Cancer Growth and Progression and as a Therapeutic Target"
9:40 – 10:00 pm	Discussion
10:00 pm –	Social – Forbes Dining Room/Patio

MONDAY – JULY 16	
7:30 – 8:15 am	Breakfast – Wilson Dining Hall
8:15 – 12:00 pm	MORNING SESSION: "Modulators of DNA damage: acquiring therapeutic index?"
	Discussion Leader: Herbie Newell, Newcastle University, Newcastle upon Tyne, UK
8:15 – 8:30 am	Introduction
8:30 – 9:10 am	Thomas Helleday, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden "Targeting DNA repair to improve anti-cancer treatments"
9:00 – 9:30 am	Discussion
9:30 – 10:00 am	Coffee Break
10:00 – 10:40 am	Alan Eastman, Dartmouth Medical School, Lebanon, NH "Can Chk1 inhibitors selectively kill tumors?"
10:40 – 11:00 am	Discussion
11:00 – 11:40 am	Ruth Plummer, Newcastle University, Newcastle upon Tyne, UK "Clinical status of modulators of the DNA damage response – challenges and ways forwards"
11:40 – 12:00 pm	Discussion
12:00 – 1:45 pm	Lunch – Wilson Dining Hall
2:00 – 4:30 pm	AFTERNOON SESSION: "Does drug scheduling or delivery matter?"
	Discussion Leader: David Spriggs, Memorial Sloan-Kettering Cancer Center, New York, NY
2:00 – 2:15 pm	Introduction
2:15 – 2:55 pm	Tito Fojo, Medical Oncology, National Cancer Institute, Bethesda MD "Why scheduling may matter or may not and the diversity of drug action"
2:45 – 3:15 pm	Discussion
3:15 – 3:55 pm	Daniel V Santi, ProLynx and University of California, San Francisco "Predictable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates"
3:55 – 4:15 pm	Discussion
4:30 – 6:00 pm	Poster Session and Social Leader: Jill Wykosky, Ludwig Institute for Cancer Research, New York NY
6:00 – 7:00 pm	Dinner—Wilson Dining Hall

7:30 – 9:45 pm	EVENING SESSION: "Modulating cell death susceptibility"
	Discussion Leader: Scott Kaufmann, Mayo Clinic, Rochester MN
7:30 – 7:45 pm	Introduction
7:45 – 8:25 pm	David Huang, Walter and Eliza Hall Institute of Medical Research, AU "Targeting Bcl-2: progress and challenges".
8:25 – 8:45 pm	Discussion
8:45 – 9:25 pm	Anthony Letai, Dana Farber Cancer Institute, Harvard Medical School, Boston MA "Personalizing cancer therapy via cancer mitochondria"
9:25 – 9:45 pm	Discussion
9:45 pm –	Social—Forbes Dining Room/Patio

TUESDAY JULY 17	
TOESDAT JOET 17	
7:30 - 8:15 am	Breakfast – Wilson Dining Hall
8:15 – 12:00 pm	MORNING SESSION: "Epigenetic regulation in cancer treatment"
	Discussion Leader: Victoria Richon, Epizyme, Cambridge MA
8:15 – 8:30 am	Introduction
8:30 – 9:10 am	James Bradner, Dana-Farber Cancer Institute, Boston MA "Inhibition of Epigenetic Reader Proteins"
9:10 – 9:30 am	Discussion
9:30 – 10:00 am	Coffee Break
10:00 – 10:40 am	Ari Melnick, Weill Cornell Medical College, New York NY "Epigenetic mechanisms in hematologic malignancies"
10:40 – 11:00 am	Discussion
11:00 – 11:40 am	Stephen B Baylin, Johns Hopkins Medicine, Baltimore MD "The possibilities for "epigenetic therapy" in solid tumors"
11:40 – 12:00 am	Discussion
12:00 – 1:45 pm	Lunch – Wilson Dining Hall
2:00 – 4:30 pm	NETWORKING AFTERNOON
4:30 – 6:00 pm	Poster Session and Social
6:00 – 7:30 pm	BBQ Dinner – Forbes Terrace

7:30 – 9:45 pm	EVENING SESSION: "Drug development morbidity and mortality conference: learning from our experience"
	Discussion Leader: Mark Ratain, University of Chicago, Chicago IL
7:30 – 7:45 pm	Introduction
7:45 – 8:25 pm	Douglas Yee, University of Minnesota, Minneapolis MN "Targeting the insulin-like growth factor receptor and the role of endocrine feedback"
8:25 – 8:45 pm	Discussion
8:45 – 9:25 pm	Philippe Bishop and Napoleone Ferrara, Genentech, San Francisco CA "Anti-angiogenics: Have we reached their full clinical potential?"
9:25 – 9:45 pm	Discussion
9:45 pm –	Social – Forbes Dining Room/Patio

WEDNESDAY JULY 18	
7:30 – 8:15 am	Breakfast – Wilson Dining Hall
8:15 – 11:00 am	MORNING SESSION: "MicroRNA as basis for cancer treatment"
	Discussion Leader: Nadia Zaffaroni, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
8:15 – 8:30 am	Introduction
8:30 – 9:10 am	Yibin Kang, Princeton University, Princeton NJ "MiRNAs as biomarker and therapeutic targets of breast cancer metastasis"
9:10 – 9:30 am	Discussion
9:30 – 10:00 am	Coffee Break
10:00 – 10:40 am	K Reed Clark, Nationwide Children's Hospital, Columbus OH "MicroRNA-based therapeutics for neoplastic and non-neoplastic disease"
10:40 – 11:00 am	Discussion
11:00 – 12:00 pm	POSTER PRESENTATIONS – Four Selected Presenters
12:05 – 1:45pm	Lunch – Wilson Dining Hall
2:00 – 5:45 pm	AFTERNOON SESSION: "New drug targets in tumor cell metabolism"
	Discussion Leader: Matthew Vander Heiden, Massachusetts Institute of Technology, Cambridge MA

2:00 – 2:15 pm	Introduction
2:15 – 2:55 pm	Chi Van Dang, University of Pennsylvania, Philadelphia PA "Targeting Myc-induced Glutamine Metabolism"
2:55 – 3:15 pm	Discussion
3:15 – 3:45 pm	Coffee Break
3:45 – 4:25 pm	Eyal Gottlieb, Beatson Institute for Cancer Research, Glasgow, UK "Metabolomic-assisted approaches to identify new cancer therapeutic targets"
4:25 – 4:45 pm	Discussion
4:45 – 5:25 pm	Kevin Marks, Agios Pharmaceuticals, Cambridge, MA "Tumorigenic consequences of genetic lesions in the metabolome"
5:25 – 5:45 pm	Discussion
6:00 – 10:00 pm	Farewell Banquet—Prospect House, to include an After Dinner Presentation by Dr. Joseph Bertino, Cancer Institute of New Jersey

THURSDAY JULY 19

7:30 - 8:30 am Breakfast – Wilson Dining Hall CHECK OUT BY 11:00 AM

SPONSOR ACKNOWLEDGEMENTS

This meeting would not be possible without the generous contributions from our many friends and colleagues:

BRISTOL MYERS SQUIBB
CELGENE
HOFFMAN LA ROCHE
JOHNSON & JOHNSON
LILLY
MERCK
PFIZER

MOLECULAR THERAPEUTICS OF CANCER 2013 CONFERENCE

University of Colorado, Boulder

Program Chair: Janet Dancey